Samsung Biologics Co.,Ltd. (207940.KS)

769.000,00 +10.000,00 (+1,32%) In data: 11:17AM KST. Mercato aperto.

Samsung Biologics Co.,Ltd.

300, Songdobio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John Chongbo Rim	CEO, President & Chairman of Board	3,12B	N/D	1961
Mr. Dong-Joong Kim	CFO, Executive VP, MD & Director	666M	N/D	1965
Mr. Pierre Catignol	Executive VP & Head of Operation Center	N/D	N/D	1968
Dr. Namjin Chung Ph.D.	Executive VP and Head of Bio R&D Centre & CSO	N/D	N/D	N/D
Mr. James J. Choi	Executive VP, Head of CDO Development Center & Head of Sales Center	569M	N/D	1967
Mr. Kyuho Lee	Executive VP, Head of People Center, & Chief Human Resource Officer	N/D	N/D	N/D
Dr. Brian Hosung Min Ph.D.	Executive VP & Head of CDO Development Center	N/D	N/D	N/D
Mr. Doyoung Heo	Vice President & Head of Finance	N/D	N/D	1975
Mr. Heekyun Lim	VP & Head of Business Consulting Team	N/D	N/D	1975
Dr. Kun Lo Ph.D.	Executive VP, Head of EPCV Center & Director	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in KRW.

Descrizione

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Governance aziendale

L'ISS Governance QualityScore di Samsung Biologics Co.,Ltd. al 29 giugno 2024 è 5. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.